Development of a Recombinant Omicron BA .1 Subunit Vaccine Candidate in Pichia pastoris
Microbial Biotechnology · 2025
DOI: 10.1111/1751-7915.70077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Biotechnology, 2025. Verfasst von Sibel Kalyoncu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Izmir Biomedicine and Genome Center, Izmir, Turkey. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, COVID-19 Vaccines, SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Türkiye Bilimsel ve Teknolojik Araştırma Kurumu.
Abstract (Originalsprache)
Low‐cost and safe vaccines are needed to fill the vaccine inequity gap for future pandemics. Pichia pastoris is an ideal expression system for recombinant protein production due to its cost‐effective and easy‐to‐scale‐up process. Here, we developed a next‐generation SARS‐CoV2 Omicron BA.1‐based recombinant vaccine candidate expressed in P. pastoris . The receptor binding domain of Omicron BA.1 spike protein (RBD‐Omicron) was produced at 0.35 g/L in supernatant. With a 60% recovery after two‐step purification, RBD‐Omicron showed 99% purity. After in vitro characterisation of purified RBD‐Omicron via chromatography, mass spectrometry, calorimetry and surface plasmon resonance‐based methods, it was injected into mice for immunization studies. Three different doses of Alum and CpG adjuvanted RBD‐Omicron were investigated and 10 μg RBD‐Omicron gave the highest antigenicity. After two doses of vaccination, IgG titers in mice serum reached to more than 10 6 . These serum antibodies also recognized earlier (Delta Plus: B.1.617.2) and later (Eris: EG.5, Pirola: BA.2.86) SARS‐CoV2 variants. The long‐term immunological response in mice was measured by analyzing serum antibody titers and T‐cell response of splenocytes after 60 weeks. Interestingly, IgG titers and Th1 response were significantly high even after a year. Omicron subvariants are dominantly circulating in the world, so Omicron sub‐lineage‐based vaccines can be used for future pandemics. The RBD‐Omicron‐based vaccine candidate developed in this study is suitable for technology transfer and transition into the clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Izmir Biomedicine and Genome Center, Izmir, Turkey.
- Faculty of Biology and CeBiTec, Bielefeld University, Bielefeld, Germany.
- Dokuz Eylul University, Izmir, Turkey.
- Dokuz Eylul University, Izmir International Biomedicine and Genome Institute, Izmir, Turkey.
- Akdeniz University, Antalya, Turkey.
ORCID-Profile: Sibel Kalyoncu, Hakan Soyturk, Mehmet Inan
Förderung
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
Zitieren
APA
Kalyoncu, S., Sayili, D., Kuyucu, A. Z., Soyturk, H., Gullu, S., Ersayan, B., Tarman, I. O., Avci, M. E., Mert, O., Haskok, U., Tekin, E., Akinturk, H., Orkut, R., Demirtas, A., Tilmensagir, I., Ulker, C., Gungor, B., & Inan, M. (2025). Development of a Recombinant Omicron BA .1 Subunit Vaccine Candidate in Pichia pastoris. Microbial Biotechnology. https://doi.org/10.1111/1751-7915.70077
Vancouver
Kalyoncu S, Sayili D, Kuyucu AZ, Soyturk H, Gullu S, Ersayan B, et al. Development of a Recombinant Omicron BA .1 Subunit Vaccine Candidate in Pichia pastoris. Microbial Biotechnology. 2025. doi:10.1111/1751-7915.70077
BibTeX
@article{Kalyoncu2025,
author = {Kalyoncu, Sibel and Sayili, Dogu and Kuyucu, Ayca Zeybek and Soyturk, Hakan and Gullu, Seyda and Ersayan, Busra and Tarman, Ibrahim Oguzhan and Avci, Mehmet Ender and Mert, Olcay and Haskok, Umut and Tekin, Ege and Akinturk, Huseyin and Orkut, Ridvan and Demirtas, Aysegul and Tilmensagir, Idil and Ulker, Ceren and Gungor, Bilgi and Inan, Mehmet},
title = {Development of a Recombinant Omicron BA .1 Subunit Vaccine Candidate in Pichia pastoris},
journal = {Microbial Biotechnology},
year = {2025},
doi = {10.1111/1751-7915.70077}
}
EUVIMED